Study of belumosudil for cGVHD in diverse patients withdrawn
NCT ID NCT05567406
First seen Feb 13, 2026 · Last updated May 02, 2026 · Updated 9 times
Summary
This study aimed to test the safety and effectiveness of the oral drug belumosudil in Black, Native American, and Pacific Islander people aged 12 and older with chronic graft-versus-host disease (cGVHD) who had already tried at least two other treatments. Participants would take the drug until their disease got worse, with follow-up for side effects and response. However, the study was withdrawn before enrolling anyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.